HARVARD BIOSCIENCE, INC. Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component
HARVARD BIOSCIENCE, INC. (HBIO) reported Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component of $1.23 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent · last filed 2026-03-13
- HARVARD BIOSCIENCE, INC. net periodic defined benefits expense (reversal of expense), excluding service cost component for the quarter ending 2025-12-31 was $1.23M.
- HARVARD BIOSCIENCE, INC. net periodic defined benefits expense (reversal of expense), excluding service cost component for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- HARVARD BIOSCIENCE, INC. net periodic defined benefits expense (reversal of expense), excluding service cost component for the quarter ending 2024-12-31 was -$1.24M.
- HARVARD BIOSCIENCE, INC. net periodic defined benefits expense (reversal of expense), excluding service cost component for the quarter ending 2024-09-30 was $1.24M.
- HARVARD BIOSCIENCE, INC. net periodic defined benefits expense (reversal of expense), excluding service cost component for fiscal 2025 was $1.23M.
- HARVARD BIOSCIENCE, INC. net periodic defined benefits expense (reversal of expense), excluding service cost component for fiscal 2024 was $0.00.
| Period end | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 3 month | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 6 month | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 9 month | Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.23M derived: sum of 2 quarters · filed 2026-03-13 | $1.23M 10-K · filed 2026-03-13 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2024-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $0.00 10-K · filed 2026-03-13 | |
| 2024-09-30 | $1.24M 10-Q · filed 2025-11-06 | $1.24M 10-Q · filed 2025-11-06 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |